MedTech CRO Huateng Science Closes RMB 10 Million Series A+ Financing

2023년 8월 30일 중국, 파이낸싱

China Guangzhou-based Huateng Science closes tens of millions of yuan Series A+ financing led by Yanghe Investment and Wanlian Tianze Capital, to expand its service base and improve the capabilities of medical device and pharmaceutical CRO service.

Huateng Science is a contract research organization (CRO) specialized in animal model construction for pharmaceutical and medical device, covering areas such as preclinical effectiveness and safety evaluation of pharmaceuticals and medical devices.

Huateng Science has a 5,000 square metres SPF grade small and large animal laboratory in its headquarter in Guangzhou City, Guangdong Province, as well as three wholly-owned subsidiaries in Foshan, Shenzhen and Chongqing, with a total laboratory area of more than 10,000 square metres. There are three divisions: Medical Device Service Division, Pharmaceutical Service Division and Research Service Division.

Huateng Science’s Medical Device CRO Division will keep expanding large animal experiments for medical devices and accelerating the innovative construction of animal disease models in cardiology, orthopaedics, spine surgery, ophthalmology and other animal disease models. It has invested nearly 100 million RMB to purchase high-end surgical imaging equipment and scientific research equipment, including DSA, CT, OCT, laparoscopy, colour ultrasound, respiratory anaesthesia machine, physiological and biochemical instrument, blood gas instrument, pathology platform, high performance liquid chromatography mass spectrometry (HPLC-MS/MS) instrument, and real-time fluorescence PCR instrument, and has built a number of 10,000 class laminar-flow clean-grade operating theatres and training operating theatres.

The Post is Available in: English – 简体中文